Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT
) by Next Generation Flow (NGF) with a sensitivity of 10⁻⁶ and a radiological CR. Responses have been sustained for 10 months. Serum BCMA (sBCMA) levels declined dynamically in parallel with haematological response, suggesting potential utility as a novel monitoring biomarker in POEMS. This case supports BCMA-directed CAR-T therapy as a safe and effective salvage strategy in RR-POEMS following ASCT failure, even in an aggressive disease context. Clinical trial registration: Not aplicable.
Authors
- Nil Albiol (ORCID: https://orcid.org/0000-0003-2942-1362)
- Marta Español‐Rego (ORCID: https://orcid.org/0000-0001-5497-2276)
- Natalia Tovar (ORCID: https://orcid.org/0000-0001-5525-476X)
- Carlos Fernández de Larrea (ORCID: https://orcid.org/0000-0003-4930-9255)
- Mercedes Montoro
- María Teresa Cibeira (ORCID: https://orcid.org/0000-0002-4036-754X)
- David F. Moreno (ORCID: https://orcid.org/0000-0002-7417-8050)
- Daniel Munárriz
- Víctor Torrecillas-Mayayo
- Pilar Ayora
- Paola Charry (ORCID: https://orcid.org/0000-0002-4777-9643)
- Luis Gerardo Rodríguez-Lobato
- Azucena González-Navarro
- Manel Juan
- Carlos Jimenez-Mira
- Aina Oliver-Caldes
- Sergio Navarro-Velasquez
- Nuria Martínez-Cibrian
- Laura Rosiñol
- Julio Delgado
- Jose Miguel Mateos
- Valentín Ortiz-Maldonado
Institutions
- Hospital Clínic de Barcelona (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Annals of Hematology
- Published
- 2026-05-11
- DOI
- https://doi.org/10.1007/s00277-026-07063-4
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00